ObjectiveTo investigate the effect of sigmart on cardiac function and serum myocardial marker levels in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) after the percutaneous coronary intervention (PCI). MethodsA total of 110 patients with NSTEMI who underwent PCI surgery in our hospital from August 2017 to January 2019 were selected as the research objects. The patients were divided into observation group and control group by the random number method, with 55 cases in each group. The control group was given conventional follow-up drug treatment after PCI, whereas the observation group was additionally administered sigmart based on the therapy in the control group, for a four-week treatment course. The pre- and post-treatment serum creatine kinase isoenzyme (CK-MB), myoglobin (MYO), serum cardiac troponin I (cTnI), brain natriuretic peptide (BNP), and heart-type fatty acid-binding protein (H-FABP) levels, as well as left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), and the occurrence of adverse cardiac events six-month follow-up after the end of treatment courses were compared between the two groups. ResultsBefore treatment, there were no statistically significant differences in serum CK-MB, MYO, cTnI, BNP, H-FABP levels between the two groups (P＞0.05). After 4 weeks of treatment, the serum CK-MB, MYO, cTnI levels of the control group increased significantly, whereas BNP, H-FABP levels decreased significantly. The control group yielded higher CK-MB, MYO, cTnI BNP, H-FABP levels as compared with the observation group, with statistically significant differences (P＜0.05). Before treatment, there were no statistically significant differences in the levels of LVEF, LVESD, and LVEDD between the two groups (P＞0.05). After 4 weeks of treatment, the LVEF level in both groups increased significantly, whereas LVESD and LVEDD levels decreased prominently. The observation group yielded a higher LVEF level and lower LVESD and LVEDD levels as compared to the control group, with statistically significant differences (P＜0.05). Six-month follow-up after the end of treatment courses, the incidence of adverse cardiac events in the observation group was significantly lower than that in the control group, with statistically significant differences (P＜0.05). ConclusionSigmart can reduce myocardial ischemia-reperfusion injury in patients with NSTEMI after PCI, improve cardiac function, and reduce the occurrence of adverse cardiac events, which is worthy of clinical promotion.

无